オプジーボ®（一般名:ニボルマブ）の安全性と有効性を評価した第Iii相臨床試験において主要評価項目が達成される  ( Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint )  Opdivo    Phase 3

By Drugs, Pharmaceutical

根治切除後の高リスク悪性黒色腫患者の術後補助療法としてオプジーボ®（一般名:ニボルマブ）の安全性と有効性を評価した第Iii相臨床試験において主要評価項目が達成される ニュースリリース｜小野薬品工業株式会社 / 
http://www.ono.co.jp/jpnw/PDF/n17_0706_1.pdf
Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint News Release / 59min ago

http://www.ono.co.jp/eng/news/pdf/sm_cn170706_1.pdf

More from tokioX :

  1. Glenmark begins Phase 3 trials of antiviral drug Favipiravir to check efficacy on COVID-19 patients in India
  2. OPDIVO: Approved for Korea “Combined use of ipilimumab · High-risk advanced stage renal cell carcinoma”
  3. FDA ：Opdivo® as the First New Medication for Certain Patients with Previously Treated Small Cell Lung Cancer
  4. 💊Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
  5. 💊European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma
  6. 👾Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy
  7. 👾Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan News Release